Translational Physician-Scientist Training Program in Oncology

肿瘤学转化医师科学家培训计划

• 批准号: 8917875
• 负责人: DONG M SHIN
• 金额: $ 27.71万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-17 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8917875
• 关键词: Physicians; Scientist; Training Programs; oncology

DESCRIPTION (provided by applicant): The Department of Hematology and Medical Oncology (HMO) and the Winship Cancer Institute at Emory University proposes a T32 Translational Physician-Scientist Training Program in Oncology. This 2.5-year Training Program (including 6 months funded internally by the HMO Department, and 2 years of T32 funding support) will enable hematology/oncology fellows to acquire a strong education in basic/translational research approaches, with the ultimate goal of establishing an independent research program for each trainee. Many studies have documented the attrition of the physician-scientist pipeline, due in large part to the challenges faced in obtaining grant funding. Providing a high level of mentoring and support is necessary to nurture the development of young physician-scientists and retain them in academic institutions. The Training Program aims to (1) provide a sufficiently large mentor pool from which to select the most appropriate research topic(s) for each trainee; (2) foster a multidisciplinary approach to cancer care and patient-oriented research through interaction with basic and clinical investigators of diverse specialties; (3) provide guidance in research design, methodology and analysis that will foster the independence of developing physician-scientists in the field of translational oncology, focused on solid tumors mainly including head and neck, lung, breast, gastrointestinal and genitourinary malignancies; and (4) guide trainees through the development and submission of their first grant application(s). The Training Program will recruit 2 residents per year with 2-3 years of prior clinical training in internal medicine, a strong desire to develop basic science research skills in oncology, and a commitment to academic medicine. All trainees will initially be recruited to the existing Hematology/Oncology Fellowship Program, and will first complete 18 months of clinical requirements for the fellowship in PGY-4 and the first half of PGY-5 (to fulfill the board eligibilty requirements of the ACGME). Trainees will then undertake 2.5 years of T32 Training Program research, from the second half of PGY-5 through PGY-7, which will encompass close mentoring in research design, methodology and analysis, support in career development and grant preparation, and participation in a rigorously defined training curriculum. Training will focus on elements critical for a successful academic career, particularly progress towards conference presentations, manuscript publications, and applications for independent research funding. Through its strong commitment to the proposed Translational Physician-Scientist Training Program in Oncology, the Emory HMO Department and the Winship intend to actively contribute to training and mentoring the next generation of physician-scientist oncologists, supporting them in the early steps of their academic research careers.

描述（由申请人提供）：埃默里大学血液学和肿瘤内科 (HMO) 系和 Winship 癌症研究所提出了 T32 肿瘤学转化医师-科学家培训计划。这项为期 2.5 年的培训计划（包括 HMO 部门内部资助的 6 个月和 T32 资助支持的 2 年）将使血液学/肿瘤学研究员获得基础/转化研究方法的深入教育，最终目标是建立一个每位学员的独立研究计划。许多研究都记录了医生-科学家渠道的消耗，这在很大程度上是由于获得拨款资金面临的挑战。 提供高水平的指导和支持对于培养年轻医师科学家的发展并留住他们在学术机构中是必要的。 培训计划的目的是（1）提供足够大的导师库，为每位学员选择最合适的研究主题； (2) 通过与不同专业的基础和临床研究人员的互动，促进癌症护理和以患者为导向的研究的多学科方法； (3) 提供研究设计、方法和分析方面的指导，以培养转化肿瘤学领域发展中医师科学家的独立性，重点关注实体瘤，主要包括头颈、肺、乳腺、胃肠道和泌尿生殖系统恶性肿瘤； (4) 指导学员制定和提交第一份拨款申请。 培训计划每年将招募 2 名住院医师，他们接受过 2-3 年的内科临床培训，有强烈的愿望发展内科基础科学研究技能 肿瘤学，以及对学术医学的承诺。所有学员最初将被招募到现有的血液学/肿瘤学奖学金计划，并将首先完成 PGY-4 和 PGY-5 上半年奖学金的 18 个月临床要求（以满足 ACGME 的董事会资格要求） 。然后，学员将进行 2.5 年的 T32 培训计划研究，从 PGY-5 的下半年到 PGY-7，其中包括研究设计、方法和分析方面的密切指导、职业发展和资助准备方面的支持，以及参与严格规定的培训课程。培训将重点关注对成功学术生涯至关重要的要素，特别是会议演讲、手稿出版和独立研究经费申请方面的进展。 通过对拟议的肿瘤学转化医师科学家培训计划的坚定承诺，埃默里 HMO 部门和 Winship 打算积极为培训和指导下一代医师科学家肿瘤学家做出贡献，支持他们学术研究的早期阶段职业生涯。